PDF(Pubmed)
Abstract：
Gastric cancer (GC) is a complex and heterogeneous disease with significant phenotypic and genetic variation. Traditional classification systems rely mainly on the evaluation of clinical pathological features and conventional biomarkers and might not capture the diverse clinical processes of individual GCs. The latest discoveries in omics technologies such as next‑generation sequencing, proteomics and metabolomics have provided crucial insights into potential genetic alterations and biological events in GC. Clustering strategies for identifying subtypes of GC might offer new tools for improving GC treatment and clinical trial outcomes by enabling the development of therapies tailored to specific subtypes. However, the feasibility and therapeutic significance of implementing molecular classifications of GC in clinical practice need to addressed. The present review examines the current molecular classifications, delineates the prevailing landscape of clinically relevant molecular features, analyzes their correlations with traditional GC classifications, and discusses potential clinical applications.
摘要：
胃癌(GC)是一种具有显著表型和遗传变异的庞杂异质性疾病。传统的分类系统主要依赖于临床病理特征和常规生物标志物的评估，并且可能无法捕获个体GC的不同临床过程。组学技术的最新发现，如下一代测序，蛋白质组学和代谢组学为GC中潜在的遗传改变和生物学事件提供了重要的见解。识别GC亚型的聚类策略可能通过开发针对特定亚型的疗法来提供改善GC治疗和临床试验结果的新工具。然而,在临床实践中实施GC分子分类的可行性和治疗意义需要解决。本综述审查了当前的分子分类，描绘了临床相关分子特征的主流景观，分析了它们与传统GC分类的相关性，并讨论了潜在的临床应用。
